Genelabs Technologies, Inc. announced today the issuance of U.S. patent No. 7,045,513 entitled "DHEA Composition and Method." The patent claims pharmaceutical formulations of
dehydroepiandrosterone, or DHEA, in certain purified polymorphic forms. DHEA is the active ingredient in Prestara, the company's investigational drug for systemic
lupus erythematosus, or lupus.